Abstract
The pharmacokinetics of styrene were investigated in male Sprague-Dawley rats and male B6C3F1 mice using the closed chamber technique. Animals were exposed to styrene vapors of initial concentrations ranging from 550 to 5000 ppm, or received intraperitoneal (i.p.) doses of styrene from 20 to 340 mg/kg or oral (p.o.) doses of styrene in olive oil from 100 to 350 mg/kg. Concentration-time courses of styrene in the chamber atmosphere were monitored and analyzed by a pharmacokinetic two-compartment model. In both species, the rate of metabolism of inhaled styrene was concentration dependent. At steady state it increased linearly with exposure concentration up to about 300 ppm; more than 95% of inhaled styrene was metabolized and only small amounts were exhaled unchanged. At these low concentrations transport to the metabolizing enzymes and not their metabolic capacity was the rate limiting step for metabolism. Pharmacokinetic behaviour of styrene was strongly influenced by physiological parameters such as blood flow and especially the alveolar ventilation rate. At exposure concentrations of styrene above 300 ppm the rate of metabolism at steady state was progressively limited by biochemical parameters of the metabolizing enzymes. Saturation of metabolism (Vmax) was reached at atmospheric concentrations of about 700 ppm in rats and 800 ppm in mice, Vmax being 224 μmol/(h·kg) and 625 μmol/(h·kg), respectively. The atmospheric concentrations at Vmax/2 were 190 ppm in rats and 270 ppm in mice. Styrene accumulates preferentially in the fatty tissue as can be deduced from its partition coefficients in olive oil∶air and water∶air which have been determined in vitro at 37°C to be 5600 and 15. In rats and mice exposed to styrene vapors below 300 ppm, there was little accumulation since the uptake was rate limiting. The bioaccumulation factor body:air at steady state (K′st*) was rather low in comparison to the thermodynamic partition coefficient body:air (Keq) which was determined to be 420. K′st* increased from 2.7 at 10 ppm to 13 at 310 ppm in the rat and from 5.9 at 20 ppm to 13 at 310 ppm in the mouse. Above 300 ppm, K′st* increased considerably with increasing concentration since metabolism became saturated in both species. At levels above 2000 ppm K′st* reached its maximum of 420 being equivalent to Keq. Pretreatment with diethyldithiocarbamate, administered intraperitoneally (200 mg/kg in rats, 400 mg/kg in mice) 15 min prior to exposure of styrene vapours, resulted in effective inhibition of styrene metabolism, indicating that most of the styrene is metabolized by cytochrome P450-dependent monooxygenases. In order to simulate chronic exposure rats and mice were exposed to 150 and 500 ppm styrene on 5 consecutive days (6 h/day). On day 6, inhalation kinetics were studied. No change in the rate of styrene metabolism was detected compared to non-pretreated controls. Intraperitoneal administration of styrene to rats and mice led to concentration-time courses in the atmosphere of the closed chamber with agreed with those predicted by the applied pharmacokinetic model. After p.o. administration of styrene to rats and mice concentration time-courses showed considerable inter-animal variability. The pharmacokinetic model was extended by a first order absorption from the gastrointestinal tract with half-lives of 0.87 h (rat) and 0.41 h (mouse) to obtain reasonable fits through the measured data. The pharmacokinetic parameters of inhaled styrene were extrapolated allometrically from rat to mouse and from rat and mouse to man. A good agreement was obtained with experimentally determined values indicating similar pharmacokinetic behaviour of styrene in these species.
Similar content being viewed by others
References
Andersen ME, Gargas ML, Ramsey JC (1984) Inhalation pharmacokinetics: Evaluating systemic extraction, total in vivo metabolism, and the time course of enzyme induction for inhaled styrene in rats based on arterial blood: inhaled air concentration ratios. Toxicol Appl Pharmacol 73: 176–187
Anderson YB, Jackson JA, Birnbaum LS (1993) Maturational changes in dermal absorption of 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) in Fischer 344 rats. Toxicol Appl Pharmacol 119: 214–220
Arms AD, Travis CC (1988) Reference physiological parameters in pharmacokinetic modeling. US Environmental Protection Agency, Washington, DC, Report No. EPA/600/6-88/004
Balant LP, Gex-Fabry M (1990) Physiological pharmacokinetic modelling. Xenobiotica 20: 1241–1257
Barale R (1991) The genetic toxicology of styrene and styrene oxide. Mutat Res 257: 107–126
Bergman K (1979) Whole-body autoradiographie and allied tracer techniques in distribution and elimination studies of some organic solvents. Scand J Work Environ Health 5 [Suppl 1]: 93–120
Bond JA (1989) Review of the toxicology of styrene. CRC Crit Rev Toxicol 19: 227–249
Bolt HM, Filser JG, Störmer F (1984) Inhalation pharmacokinetics based on gas uptake studies V. Comparative pharmacokinetics of ethylene and 1,3-butadiene in rats. Arch Toxicol 55: 213–218
BUA (1990) Beratergremium für umweltrelevante Altstoffe (BUA) der Gesellschaft Deutscher Chemiker, Styrol (Ethenylbenzol). BUA-Stoffbericht 48, Verlag Chemie, Weinheim, Germany
Caperos JR, Humbert B, Droz PO (1979) Exposition au styrène. II. Bilan de l' absorption, de l'excrétion et du métabolisme sur des sujets humains. Int Arch Occup Environ Health 42: 223–230
Carlsson A (1981) Distribution and elimination of14C-styrene in the rat. Scand J Work Environ Health 7: 45–50
Caster WO, Poncelet J, Simon AB, Armstrong WD (1956) Tissue weights of the rats. I. Normal values determined by dessection and chemical methods. Proc Soc Exper Biol Med 91: 122–126
Conti B, Maltoni C, Perino G, Ciliberti A (1988) Long-term cancerogenicity bioassays on styrene administered by inhalation, ingestion and injection and styrene oxide administered by ingestion in Sprague-Dawley rats, and para-methylstyrene administered by ingestion in Sprague-Dawley rats and Swiss mice. Ann NY Acad Sci 534: 203–235
Csanády GA, Filser JG (1990) SOLVEKIN: a new program for solving pharmaco- and toxicokinetic problems. Presented on the International Workshop on Pharmacokinetic Modelling in Occupational Health. March 4–8. Leysin, Switzerland
Danishefski I, Willhite M (1954) The metabolism of styrene in the rat. J Biol Chem 211: 549–553
Davidson IWF, Parker JC, Beliles RP (1986) Biological basis for extrapolation across mammalian species. Regul Toxicol Pharmacol 6: 211–237
Dawson NJ (1970) Body composition of inbred mice (mus musculus). Comp Biochem Physiol 37: 589–593
Denk B (1990) Abschätzung des kanzerogenen Risikos von Ethylen und Ethylenoxid für den Menschen durch Speziesextrapolation von der Ratte unter Berücksichtigung der Pharmakokinetik. GSF-Bericht 20/90. Neuherberg, Germany
Droz PO, Fernández J (1977) Solubility of organic solvents. I. Gas chromatographic determination of olive oil-gas partition coefficients. Helv Chim Acta 60 Fasc 2: 454–458
El Masri AM, Smith JN, Williams RT (1958) The metabolism of alkyl-benzenes: phenylacethylene and phenylethylene (styrene). Biochem J 68: 199–204
Elovaara E, Vainio H, Pfäffli P, Collan Y (1979) Effects of intermittent styrene inhalation, ethanol intake and their combination on drug biotransformation in rat liver and kidneys. Med Biol 57: 321–327
Elovaara E, Engström K, Nakajima T, Park SS, Gelboin HV, Vainio H (1991) Metabolism of inhaled styrene in acetone-, phenobarbital- and 3-methylcholanthrene-pretreated rats: stimulation and stereochemical effects by induction of cytochromes P450IIE1, P450IIB and P450IA. Xenobiotica 21: 651–661
Fernández JG, Caperos JR (1977) Exposition au Styrène. I. Etude expérimentale de l'absorbtion et de l'excrétion pulmonaires sur des sujets humains. Int Arch Occup Environ Health 40: 1–12
Filser JG (1992) The closed chamber technique — uptake, endogenous production, excretion, steady-state kinetics and rates of metabolism of gases and vapors. Arch Toxicol 66: 1–10
Filser JG, Bolt HM (1979) Pharmacokinetics of halogenated ethylenes in rats. Arch Toxicol 42: 123–136
Filser JG, Bolt HM (1984) Inhalation pharmacokinetics based on gas uptake studies VI. Comparative evaluation of ethylene oxide and butadiene monoxide as exhaled reactive metabolites of ethylene and 1,3-butadiene in rats. Arch Toxicol 55: 219–223
Filser JG, Peter H, Bolt HM, Fedtke N (1987) Pharmacokinetics of the neurotoxine n-hexan in rat and man. Arch Toxicol 60: 77–80
Fiserova-Bergerova V (1983) Modeling of metabolism and excretion in vivo. In: Fiserova-Bergerova V (ed) Modeling of inhalation exposure to vapors: uptake, distribution, and elimination. Vol. I. CRC Press, Boca Raton, Florida, pp 101–133
Foureman GL, Harris C, Guengerich FP, Bend JR (1989) Stereoselectivity of styrene oxidation in microsomes and in purified cytochrome P-450 enzymes from rat liver. J Pharmacol Exp Ther 248: 492–497
Geyer HJ, Scheunert I, Rapp K, Kettrup A, Korte F, Greim H, Rozman K (1991) Correlation between acute toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and total body fat content in mammals. Toxicology 65: 97–107
Gross EA, Morgan KT (1992) Architecture of the nasal passages and larynx. In: Parent RA (ed) Comparative biology of the normal lung. CRC Press, Boca Raton, Florida, pp 7–25
Guengerich FP, Kim D-H, Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4: 168–179
Guillemin MP, Bauer D (1979) Human exposure to styrene. III. Elimination kinetics of urinary mandelic and phenylglyoxylic acids after single experimental exposure. Int Arch Occup Environ Health 44: 249–263
Hallier E, Filser JG, Bolt HM (1981) Inhalation pharmacokinetics based on gas uptake studies II. Pharmacokinetics of acetone in rats. Arch Toxicol 47: 293–304
Hartmann M, Denk B, Kessler W, Filser JG (1990) Inhalation pharmacokinetics and endogenous production of isoprene in humans. In: Schuckmann F, Schopper-Jochum S (eds) Verhandlungen der Deutschen Gesellschaft für Arbeitsmedizin e. V. Gentner Verlag, Stuttgart, pp 529–531
Henschler D (ed) (1987) Styrol. Toxikologisch-Arbeitsmedizinische Begründung von MAK-Werten, 13th edn. Verlag Chemie, Weinheim
Ikeda M, Ohtsuji H, Imamura T (1972) In vivo suppression of benzene and styrene oxidation by coadministered toluene and effects of phenobarbital. Xenobiotica 2: 101–106
Johanson G, Filser JG (1992) Experimental data from closed chamber gas uptake studies in rodents suggest lower uptake rate of chemical than calculated from literature values on alveolar ventilation. Arch Toxicol 66: 291–295
Kessler W, Denk B, Filser JG (1989) Species-specific inhalation pharmacokinetics of 2-nitropropane, methyl ethyl ketone and n-hexane. In: Travis CC (ed) Biologically-based methods for cancer risk assessment. NATO ASI Series A: Life Sciences Vol. 159. Plenum, New York, pp 123–139
Kim HJ, Bruckner JV, Dallas CE, Gallo JM (1990) Effect of dosing vehicles on the pharmacokinetics of orally administered carbon tetrachloride in rats. Toxicol Appl Pharmacol 102: 50–60
Laib RJ, Tucholski M, Filser JG, Csanády GyA (1992) Pharmacokinetic interaction between 1,3-butadiene and styrene in Sprague-Dawley rats. Arch Toxicol 66: 310–314
Leibman KC, Ortiz E (1970) Epoxide intermediates in microsomal epoxidation of olefins to glycols. J Pharmacol Exp Ther 173: 242–246
Lijinski W (1986) Rat and mouse forestomach tumors induced by chronic oral administration of styrene oxide. J Natl Cancer Inst 77: 471–476
Löf A (1986) Toxicokinetics of styrene. Biotransformation and covalent binding. Arbete och Hälsa, Vetenskaplik Skriftserie No. 6, Solna, Sweden
Löf A, Gullstrand E, Nordqvist MB (1983) Tissue distribution of styrene, styrene glycol and more polar styrene metabolites in the mouse. Scand J Work Environ Health 9: 419–430
Lutz RJ, Dedrick RL, Matthews HB, Eling TE, Anderson MW (1977) A preliminary pharmacokinetic model for several chlorinated biphenyls in the rat. Drug Metab Dispos 5: 386–396
Maltoni C, Failla G, Kassapidis S (1979) First experimental demonstration of the carcinogenic effects of styrene oxide. Med Lav 5: 358–362
Marniemi J, Suolinna EM, Kaartinen N, Vainio H (1977) Covalent binding of styrene oxide to rat liver macromolecules in vivo and in vitro. In: Ullrich V, Roots I, Hildebrandt A, Estabrook RW, Conney AH (eds) Microsomes and drug oxidations. Pergamon, Oxford, pp 698–702
Mendrala AL, Langvardt PW, Nitschke KD, Quast JF, Nolan RJ (1993) In vitro kinetics of styrene and styrene oxide metabolism in rat, mouse and human. Arch Toxicol 67: 18–27
NIOSH (1983) Criteria for a recommended standard occupational exposure to styrene. PB84-148295. National Institute for Occupational Safety and Health, Cincinnati, OH, DHHS (NIOSH) publication No. 83-119
Nordqvist MB, Löf A, Osterman-Golkar S, Walles SAS (1985) Covalent binding of styrene and styrene-7,8-oxide to plasma proteins, hemoglobin and DNA in the mouse. Chem Biol Interact 55: 63–73
Normandeau J, Chakrabarti S, Brodeur J (1984) Influence of simultaneous exposure to acrylonitrile and styrene on the toxicity and metabolism of styrene in rats. Toxicol Appl Pharmacol 75: 346–349
Ohtsuji H, Ikeda M (1971) The metabolism of styrene in the rat and the stimulatory effect of phenobarbital. Toxicol Appl Pharmacol 18: 312–328
Pantarotto C, Fanelli R, Belletti I, Bidoli F (1980) Determination of styrene in biological specimens by gas chromatography-selected ion monitoring: Distribution in mice. Anal Biochem 105: 340–347
Plotnick HB, Weigel WW (1979) Tissue distribution and excretion of14C-styrene in male and female rats. Res Commun Chem Pathol Pharmacol 24: 515–524
Ponomarkov V, Carbal JRP, Wahrendorf J, Galendo D (1984) A carcino-genicity study of styrene-7,8-oxide in rats. Cancer Lett 24: 95–101
Ramsey JC, Andersen ME (1984) A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol Appl Pharmacol 73: 159–175
Ramsey JC, Young JD (1978) Pharmacokinetics of inhaled styrene in rats and humans. Scand J Work Environ Health 4 [Supp 12]: 84–91
Ramsey JC, Young JD, Karbowski RJ, Chenoweth MB, McCarty LP, Braun WH (1980) Pharmacokinetics of inhaled styrene in human volunteers. Toxicol Appl Pharmacol 53: 54–63
Sato A, Nakajima T (1979) Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. Br J Ind Med 36: 231–234
Sato A, Nakajima T (1987) Pharmacokinetics of organic solvent vapors in relation to their toxicity. Scand J Work Environ Health 13: 81–93
Sauerhoff MW, Braun WH (1976) Report: The fate of styrene in rats following an inhalation exposure to 14C-styrene. Dow Chemical, Midland, USA
Schmidt RF, Thews G (1977) Physiologie des Menschen. Springer, Berlin Heidelberg New York
Schwegler U (1991) Pharmakokinetik von Styrol bei Ratte und Maus. GSF-Bericht 15/91. Neuherberg, Germany
Schwegler U, Filser JG (1989) Inhalation kinetics of styrene in rat and mouse. Naunyn-Schmiedeberg's Arch Pharmacol Suppl 339: R14
Schwegler U, Filser JG (1990) Pharmakokinetic von Styrol bei Ratte und Maus und Bestimmung von Styrol-7,8-oxid im Blut von Ratten. In: Schuckmann F, Schopper-Jochum S (eds) Verhandlungen der Deutschen Gesellschaft für Arbeitsmedizin e.V. Gentner, Stuttgart, pp 419–425
Shen J, Kessler W, Denk B, Filser JG (1989) Metabolism and endogenous production of ethylene in rat and man. Arch Toxicol Suppl 13: 237–239
Siegers CP, Filser JG, Bolt HM (1978) Effect of dithiocarb on metabolism and covalent binding of carbon tetrachloride. Toxicol Appl Pharmacol 46: 709–716
Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Howells GP, Tipton IH (1975) Report of the task group on reference man. A report prepared by a task group of Committee 2 of the International Commission on Radiological Protection. Pergamon, Oxford New York Toronto Sydney Braunschweig
Stewart RD, Dodd HC, Baretta ED, Schaffer AW (1968) Human exposure to styrene vapor. Arch Environ Health 16: 656–662
Teramoto K, Horiguchi S (1979) Absorption, distribution and elimination of styrene in man and experimental animals. Arh Hig Rada Toksikol 30 [suppl]: 431–437
Tuey DB, Matthews HB (1980) Use of a physiological compartmental model for the rat to describe the pharmacokinetics of several chlorinated biphenyls in the mouse. Drug Metabol Dispos 8/6: 397–403
Van Rees H (1974) The partition coefficients of styrene between blood and air and between oil and blood. Int Arch Arbeitsmed 33: 39–47
Watabe T, Isobe M, Yoshikawa K, Takabatake E (1978) Studies on metabolism and toxicity of styrene. I. Biotransformation of styrene to styrene glycol via styrene oxide by rat liver microsomes. J Pharm Dyn 1: 98–104
WHO (1983) Styrene. Environmental Health Criteria 26. World Health Organization, Geneva, Switzerland
Withey JR (1976) Quantitative analysis of styrene monomer in polystyrene and food including some preliminary studies of the uptake and pharmacodynamics of the monomer in rats. Environ Health Perspect 17: 125–133
Withey JR (1978) The toxicology of styrene monomer and its pharmacokinetics and distribution in the rat. Scand J Work Environ Health 4 [suppl. 2]: 31–40
Withey JR, Collins PG (1977) Pharmacokinetics and distribution of styrene monomer in rats after intravenous administration. J Toxicol Environ Health 3: 1011–1020
Withey JR, Collins PG (1979) The distribution and pharmacokinetics of styrene monomer in rats by the pulmonary route. J Environ Pathol Toxicol 2: 1329–1342
Woodruff TJ, Bois FY, Auslander D, Spear RC (1992) Structure and parameterization of pharmacokinetic models: their impact on model predictions. Risk Anal 12: 189–201
Young JD, Ramsey JC, Blau GE, Karbowski RJ, Nitschke KD, Slauter RW, Braun WH (1979) Pharmacokinetics of inhaled or intraperitoneally administered styrene in rats. In: Toxicology and occupational medicine. Proceedings of the tenth interamerican conference on toxicology and occupational medicine. Elsevier/North-Holland, New York, pp 297–310
Author information
Authors and Affiliations
Additional information
Results of these studies were presented in part at the 30th Spring Meeting of the Deutsche Gesellschaft für Pharmakologie und Toxikologie (Schwegler and Filser 1989) and at the 30. Jahrestagung der Deutschen Gesellschaft für Arbeitsmedizin (Schwegler and Filser 1990).
Rights and permissions
About this article
Cite this article
Filser, J.G., Schwegler, U., Csanády, G.A. et al. Species-specific pharmacokinetics of styrene in rat and mouse. Arch Toxicol 67, 517–530 (1993). https://doi.org/10.1007/BF01969264
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01969264